1
|
Santoleri F, Ranucci E, La Barba G, Colasanto I, Scaldaferri M, Cattel F, Federici F, Rossi C, Di Biagio K, Scortechini AR, Musicco F, Torquati G, Frazzetto A, Vozza A, de Rosa C, Lanzillo R, Monteverde M, Luciano L, Pane F, Pasquazi A, Celeste MG, Cantonetti M, Franceschini L, Rizzo M, Costantini A. Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life. Curr Med Res Opin 2021; 37:477-481. [PMID: 33459083 DOI: 10.1080/03007995.2021.1876006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND The use of dasatinib and nilotinib in the treatment of patients with chronic myeloid leukemia represents a valid therapeutic option for patients resistant or intolerant to imatinib. In this multicentre study, adherence, persistence and efficacy in real life over two years of treatment were evaluated. MATERIALS AND METHODS Adherence to treatment was calculated as the ratio between the dose received and the prescribed dose. The dose received was calculated using pharmacy refill data. The persistence with treatment was calculated as the difference between the end and the beginning of the treatment. Efficacy was assigned as Progression-Free Survival (PFS) and Events-Free Survival (EFS) and represented through the Kaplan-Meier curve. RESULTS The number of patients analysed was 117, 70 treated with dasatinib and 47 with nilotinib. Adherence to treatment for dasatinib and nilotinib at two years was 0.91 and 0.82 respectively. Persistence at two years was 77% while the PFS was 92% for both drugs in the study. CONCLUSION Adherence to the treatment calculated over two years showed a superiority of dasatinib over nilotinib. Nevertheless, the efficacy in terms of PFS and EFS is superimposable between the two drugs in the study.
Collapse
Affiliation(s)
| | - Elena Ranucci
- Department Pharmacist, Hematological Oncology Department, Pescara General Hospital, Pescara, Italy
| | - Gaetano La Barba
- Hematologist, Hematological Oncology Department, Pescara General Hospital, Pescara, Italy
| | - Irene Colasanto
- Hospital pharmacist, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - Matilde Scaldaferri
- Hospital pharmacist, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - Francesco Cattel
- Hospital pharmacist, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | | | | | - Katiuscia Di Biagio
- Environmental Epidemiology Unit - Regional Environmental Protection Agency of Marche, Ancona, Italy
| | - Anna Rita Scortechini
- Hematologist, Hematology Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
| | - Felice Musicco
- Hospital Pharmacist at Regina Elena - San Gallicano cancer and dermatological Institute, Rome, Italy
| | - Giancarlo Torquati
- Hospital Pharmacist at Regina Elena - San Gallicano cancer and dermatological Institute, Rome, Italy
| | - Angela Frazzetto
- Hospital Pharmacist at Regina Elena - San Gallicano cancer and dermatological Institute, Rome, Italy
| | - Antonietta Vozza
- Hospital pharmacist, Azienda Ospedaliera Universitaria "Federico II", Napoli, Italy
| | - Caterina de Rosa
- Hospital pharmacist, Azienda Ospedaliera Universitaria "Federico II", Napoli, Italy
| | - Rosaria Lanzillo
- Hospital pharmacist, Azienda Ospedaliera Universitaria "Federico II", Napoli, Italy
| | - Maria Monteverde
- Biologist, Department of Clinical Medicine and Surgery, Federico II University Medical School, Napoli, Italy
| | - Luigia Luciano
- Hematologist, Department of Clinical Medicine and Surgery, Federico II University Medical School, Napoli, Italy
| | - Fabrizio Pane
- Hematologist, Department of Clinical Medicine and Surgery, Federico II University Medical School, Napoli, Italy
| | - Arianna Pasquazi
- Hospital pharmacist, Policlinico Tor Vergata PTV Foundation, Roma, Italy
| | | | - Maria Cantonetti
- Hematologist, Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata PTV Foundation, Roma, Italy
| | - Luca Franceschini
- Hematologist, Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata PTV Foundation, Roma, Italy
| | - Manuela Rizzo
- Hematologist, Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata PTV Foundation, Roma, Italy
| | | |
Collapse
|
2
|
Zackova D, Klamova H, Belohlavkova P, Stejskal L, Necasova T, Semerad L, Weinbergerova B, Srbova D, Voglova J, Cicatkova P, Sustkova Z, Hornak T, Baranova J, Prochazkova J, Mayer J. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. Leuk Lymphoma 2020; 62:194-202. [PMID: 33021423 DOI: 10.1080/10428194.2020.1827242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients with BCR-ABL1 transcript level ≤10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
Collapse
Affiliation(s)
- Daniela Zackova
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
| | - Hana Klamova
- Institute of Hematology and Blood Transfusion, Praha, Czech Republic
| | - Petra Belohlavkova
- 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Lukas Stejskal
- Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic
| | - Tereza Necasova
- Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
| | - Lukas Semerad
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
| | - Barbora Weinbergerova
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
| | - Dana Srbova
- Institute of Hematology and Blood Transfusion, Praha, Czech Republic
| | - Jaroslava Voglova
- 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Petra Cicatkova
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
| | - Zuzana Sustkova
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
| | - Tomas Hornak
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
| | - Jana Baranova
- Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
| | - Jirina Prochazkova
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
| | - Jiri Mayer
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.,Central European Institute of Technology, Brno, Czech Republic
| |
Collapse
|